• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>RailAmerica

RailAmerica

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association

    Ra Pharmaceuticals Presents Data on Oral Small Molecule Complement Inhibitors at the 22nd Congress of the European Hematology Association

  2. Heart Endovascular & Rhythm of Texas Begins First Commercial, FDA-Cleared, In-Patient Use of DABRA™ to Treat Peripheral Artery Disease

    Heart Endovascular & Rhythm of Texas Begins First Commercial, FDA-Cleared, In-Patient Use of DABRA™ to Treat Peripheral Artery Disease

  3. Cellular Machine-to-Machine (M2M) Modules - Global Strategic Business Report 2017 - Leading Players are AT&T, China Mobile, China Unicom, Deutsche Telekom, Sprint, Telefonica, Verizon, Vodafone - ...

    Cellular Machine-to-Machine (M2M) Modules - Global Strategic Business Report 2017 - Leading Players are AT&T, China Mobile, China Unicom, Deutsche Telekom, Sprint, Telefonica, Verizon, Vodafone - Research and Markets

  4. Top 3 Emerging Trends Impacting the Global Anti-Inflammatory Therapeutics Market from 2017-2021: Technavio

    Top 3 Emerging Trends Impacting the Global Anti-Inflammatory Therapeutics Market from 2017-2021: Technavio

  5. Tally Automates Credit Card Management to Replace Consumer Stress with Confidence

    Tally Automates Credit Card Management to Replace Consumer Stress with Confidence

  6. Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth - Research and Markets

    Global Immunology Drugs Market to 2022 - Increasing Prevalence, Repositioning Opportunities and Strong Uptake of Interleukin Receptor Inhibitors to Drive Growth - Research and Markets

  7. IdenTrust Achieves Direct Trusted Agent Accreditation Program from EHNAC and DirectTrust

    IdenTrust Achieves Direct Trusted Agent Accreditation Program from EHNAC and DirectTrust

  8. Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

    Pfizer Announces Results from XELJANZ® (tofacitinib citrate) ORAL Strategy Study Published in The Lancet and Presented at the EULAR Annual Congress

  9. Bristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular ...

    Bristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

  10. Norsk Titanium Announces Strategic Investment from an Affiliate of Fortress Investment Group

    Norsk Titanium Announces Strategic Investment from an Affiliate of Fortress Investment Group

12345

©2017 Morningstar Advisor. All right reserved.